A review reports that tirzepatide, a weight-loss drug marketed as Mounjaro, may improve sleep-related breathing problems, including severe snoring and sleep apnoea symptoms. The outlets state that results indicate a substantial reduction in these symptoms for some users.
According to the review as described in both reports, up to half of patients taking tirzepatide see their sleep apnoea symptoms significantly improve. The coverage frames this as an additional potential benefit of the drug beyond weight loss. Both articles draw on the same core finding and highlight sleep improvement rather than weight-loss outcomes, with no substantial differences in emphasis between the two sources provided.
The reports do not detail the number of studies included, participant characteristics, study length, or how outcomes were measured. They also do not discuss risks, eligibility, or whether improvements translate into long-term health outcomes. Overall, the news coverage presents the findings as preliminary evidence from a review rather than a definitive clinical recommendation.
